U.S. Markets closed

Eyenovia, Inc. (EYEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.3900-0.0200 (-0.59%)
At close: 4:00PM EDT

Eyenovia, Inc.

295 Madison Avenue
Suite 2400
New York, NY 10017
United States
917 289 1117
http://www.eyenoviabio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees27

Key Executives

NameTitlePayExercisedYear Born
Dr. Tsontcho Ianchulev M.P.H., M.D., MPHCEO, Pres, Chief Medical Officer & Director733.44kN/A1974
Mr. John P. GandolfoCFO & Sec.504.33kN/A1961
Mr. Michael M. RoweVP of Marketing362.33kN/A1963
Alexander LoboInvestor ContactN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet. It focuses on achieving clinical microdosing of next-generation formulations of ophthalmic pharmaceutical agents using its ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. The company, through its proprietary delivery technology, is developing smart ophthalmic therapies while targeting new indications for which there are currently no drug therapies approved by the U.S. Food and Drug Administration. Eyenovia, Inc. focuses on advancing its MicroLine program for the improvement in near vision in patients with presbyopia in Phase III development. Its other product candidates include MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma, open angle glaucoma, and ocular hypertension; MicroStat, which has completed Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of red eye and itch relief lubrication; and MicroPine for the treatment of progressive myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.

Corporate Governance

Eyenovia, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.